Regulus Therapeutics (RGLS) Competitors

Verastem (NASDAQ:VSTM) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership, community ranking and earnings.

Do analysts rate VSTM or RGLS?

Verastem presently has a consensus target price of $13.88, suggesting a potential upside of 106.17%. Regulus Therapeutics has a consensus target price of $12.75, suggesting a potential upside of 750.00%. Given Regulus Therapeutics' higher probable upside, analysts plainly believe Regulus Therapeutics is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
Regulus Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is VSTM or RGLS more profitable?

Regulus Therapeutics' return on equity of -53.07% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	N/A	-332.73%	-73.97%
Regulus Therapeutics	N/A	-53.07%	-48.58%

Does the media refer more to VSTM or RGLS?

In the previous week, Verastem had 17 more articles in the media than Regulus Therapeutics. MarketBeat recorded 26 mentions for Verastem and 9 mentions for Regulus Therapeutics. Regulus Therapeutics' average media sentiment score of 1.30 beat Verastem's score of 0.28 indicating that Regulus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	4 Very Positive mention(s)	6 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Regulus Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger earnings and valuation, VSTM or RGLS?

Regulus Therapeutics has lower revenue, but higher earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$10M	34.65	-$87.37M	-$3.50	-1.92
Regulus Therapeutics	N/A	N/A	-$30.04M	-$0.87	-1.72

Do insiders & institutionals believe in VSTM or RGLS?

88.4% of Verastem shares are held by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are held by institutional investors. 2.2% of Verastem shares are held by insiders. Comparatively, 4.4% of Regulus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Which has more risk and volatility, VSTM or RGLS?

Verastem has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.

Does the MarketBeat Community prefer VSTM or RGLS?

Verastem received 122 more outperform votes than Regulus Therapeutics when rated by MarketBeat users. Likewise, 65.32% of users gave Verastem an outperform vote while only 63.99% of users gave Regulus Therapeutics an outperform vote.

Company	Underperform	Outperform
Verastem	Outperform Votes 616 65.32%	Underperform Votes 327 34.68%
Regulus Therapeutics	Outperform Votes 494 63.99%	Underperform Votes 278 36.01%

Summary

Regulus Therapeutics beats Verastem on 10 of the 15 factors compared between the two stocks.